NIH awards $4.8 million to UA Valley Fever Center for Excellence

August 24th, 2017
The Valley Fever Center for Excellence (VFCE) at the University of Arizona College of Medicine - Tucson has been awarded a four-year, $4.8 million grant for research to speed development of a vaccine to combat Valley fever, the sometimes deadly respiratory illness caused by Coccidioides spores found in soils of the U.S. Southwest.

The funding comes from the National Institute of Allergy and Infectious Diseases (NIAID), a unit of the National Institutes of Health (NIH), and aims to enable development of a live, yet safe, vaccine to prevent this fungal disease (also known as coccidioidomycosis, or cocci).

"We are very excited to receive this award," said John N. Galgiani, MD, principal investigator on the project, a UA professor of medicine and the center's founding and current director. "This reflects the scientific validity of our plans and the funds will greatly accelerate the vaccine's development."

The vaccine candidate is known as delta-CPS1 and was invented at the UA. The research goal is to test and possibly license this vaccine in dogs to protect them from contracting Valley fever. Anivive Lifesciences Inc., a California-based biotechnology company, has licensed the vaccine from the UA through Tech Launch Arizona and will provide additional investment and expertise to fully develop this dog vaccine. Tech Launch is the UA's commercialization arm, helping transform UA innovations and discoveries into intellectual property, inventions and technology through licensing agreements with private industry. The UA BIO5 Institute also has assisted in this translational project.

Scientists at Colorado State University also are collaborating on this project through CSU's College of Veterinary Medicine and Biomedical Sciences and the lab of Richard A. Bowen, DVM, PhD. If proven safe and effective in dogs, the next step likely would be evaluation and possible approval of a vaccine to prevent Valley fever in humans.

"The awarding of this grant to Dr. Galgiani's group will serve to help us advance the introduction of a vaccine for both man and animals to prevent this truly devastating disease," said David Bruyette, DVM, DACVIM, chief medical officer at Anivive Lifesciences.

This recent award comes on the heels of a $2.7 million NIH/NIAID grant the VFCE also received for collaborative work to understand the human genetics behind susceptibility to the worst forms of Valley fever (supported by NIAID under Award No. U01AI122275). That research addresses the question of why some people get so sick from this fungus while other's immune systems are able to control it, resulting in only a mild illness, if any at all. These efforts could lead to precision medicine solutions specific to an individual at risk and possible new approaches to treatment by immunologic response modifiers.

With more than 90 percent of U.S. human infection cases occurring in Arizona and California, Valley fever is the most significant fungal public health problem in the Southwest. Each year, Valley fever is responsible for 50,000 illnesses and more than 150 deaths, with a cost of half a billion dollars in health care and lost productivity, according to the U.S. Centers for Disease Control and Prevention. Current therapies for more severe instances of this disease are not curative and may need to be continued for life.

Provided by University of Arizona

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Climate change may lead to bigger atmospheric rivers

A new NASA-led study shows that climate change is likely to intensify extreme weather events known as atmospheric rivers across most of the globe by the end of this century, while slightly reducing their number.

A better B1 building block

Humans aren't the only earth-bound organisms that need to take their vitamins. Thiamine – commonly known as vitamin B1 – is vital to the survival of most every living thing on earth. But the average bacterium or plant ...

Simulations show how beta-amyloid may kill neural cells

Beta-amyloid peptides, protein fragments that form naturally in the brain and clump into plaques in Alzheimer's disease patients, are thought to be responsible for neuron death, but it hasn't been clear how the substances ...

Plant symbioses—fragile partnerships

All plants require an adequate supply of inorganic nutrients, such as fixed nitrogen (usually in the form of ammonia or nitrate), for growth. A special group of flowering plants thus depends on close symbiotic relationships ...

Bumblebees confused by iridescent colors

Iridescence is a form of structural colour which uses regular repeating nanostructures to reflect light at slightly different angles, causing a colour-change effect.